3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Sarcoma
2
Genitourinary
2
Dermatologic
2
Breast
2
Tumor-Agnostic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Conditions
Melanoma
8
Uveal Melanoma
2
Neoplasm Metastasis
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Lung Neoplasms
1
Endometrial Neoplasms
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
36
Cyclophosphamide
24
Nivolumab
23
Ipilimumab
22
aldesleukin
19
Interleukin-2
15
fludarabine
14
Specimen Handling
12
Dacarbazine
11
fludarabine phosphate
10
Magnetic Resonance Spectroscopy
10
Temozolomide
9
Radiosurgery
9
Biopsy
9
cemiplimab
8
Paclitaxel
8
dabrafenib
5
binimetinib
5
Vemurafenib
5
Radiotherapy
5
Carboplatin
5
trametinib
4
sargramostim
4
encorafenib
4
avelumab
4
Pemetrexed
4
Leucovorin
4
Fluorouracil
4
Cisplatin
4
Bevacizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
Colony-Stimulating Factors
×
Dermatologic
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled
NCT01363206
2020-03-19
GIPI
Northern California Melanoma Center
Phase 2
Completed
29 enrolled